Virtu Financial LLC has recently invested in
DexCom, Inc. (NASDAQ:DXCM) amidst mixed views from analysts. Some suggest retaining
DexCom stock in your portfolio due to promising returns, citing the company's brighter outlook for 2025 and applauding their momentum for the long-term. Others, like
Jim Cramer, express reduced conviction in the company due to recent performances, as DexCom's shares declined notably in Q2 and Q3, partly due to an earnings miss and reported issues with their sales force. Despite this, some entities, like
Geode Capital Management LLC and
Y Intercept Hong Kong Ltd, have increased their shareholdings in DexCom. The
European court also recently ruled in favor of
Abbott in a patent spat against DexCom. As a direct result of these, DexCom has faced investor and analyst backlash, with Hagens Berman accusing the company of misleading investors. The growth seems decelerated, and they are now seeking damage control through partnerships, including an investment in
ΕURA too. However, DexCom is performing well in projected key metrics and is emerging as a recommended stock for many investors. Furthermore, the company is also hailed as one of the top stocks with improving technical ratings by Piper Sandler.
Dexcom DXCM News Analytics from Mon, 17 Jun 2024 07:00:00 GMT to Sat, 14 Dec 2024 11:13:25 GMT -
Rating -3
- Innovation 3
- Information 2
- Rumor -6
